Calculus Capital has successfully exited its investors’ shares in Epistem – a personalised medicine and biotechnology company commercialising its expertise in stem cells, infectious disease diagnostics and pharmacogenomics as a guide to therapy selection.
Calculus sold the shares in Epistem in May 2014, through a placing in the market, delivering yet another great return to our investors.
Fund 8: In price per share: 163p
Out price per share: 320p
Epistem was founded in 2001 as a ‘spinout’ from the Paterson Institute. The firm now operates three distinct business divisions: Preclinical Research Services, Personalised Medicine and Novel Therapies.
Epistem’s Preclinical Research division services a number of big pharma groups including GlaxoSmithKline, Novartis and the US National Institutes of Health. One of Epistem’s most successful products is its Genedrive® diagnostic product, which is a handheld molecular (PCR) diagnostic instrument which generates results within 3060
minutes, testing for diseases such as Tuberculosis (TB). Epistem is in ongoing discussions with the Global Health Investment Fund to enter into a collaboration for the deployment of Genedrive® in low income countries.